Bengt Liljas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bengt Liljas has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Björn Lindgren
LUCHE (Lund University Centre for Health Economics), AstraZeneca
1 shared publication- Grammati Sarri
Cytel, Inc., London, UK
1 shared publication Göran S. Karlsson
AstraZeneca Sverige, Södertalje, Sweden
1 shared publicationKaren Blumenschein
1 shared publication- Keith R. Abrams
Department of Statistics, University of Warwick, Coventry, UK
1 shared publication Kellie Ryan
Global Medical Affairs, AstraZeneca, Gaithersburg, MD, USA
1 shared publication
Latest Publications
- Open Access
- 8 April 2026
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 14 (2) , 20
Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization
Methodological guidelines for real-world evidence (RWE) in European Union (EU) joint clinical assessments (JCA) are lacking. This manuscript explores RWE potential in EU health technology assessment (HTA) and offers recommendations for generating high-quality RWE. An environmental scan of peer-reviewed and gray literature was conducted to review RWE frameworks and documents in EU regulatory and HTA decision-making. Extraction elements were standardized across key RWE themes: data quality, methodological rigor, stakeholder engagement, and applications. In JCA, RWE has multiple uses, including informing PICO simulation exercises, understanding disease landscape, identifying prognostic factors and effect modifiers, and directly or indirectly informing comparative clinical assessments. Methodological guidance from the HTA Coordination Group is limited to cases in which evidence from non-randomized studies is used as direct inputs in comparative assessments. Individual HTA bodies provide more detailed guidance, missing an opportunity to leverage RWE within JCAs that can offer insight for local Member State submissions. Generating high-quality RWE that is credible, actionable, and acceptable for JCA submissions and local HTA bodies requires careful attention to methodological considerations and early planning. Broader RWE integration that reflects patient journeys is needed. Expanding the HTA Coordination Group guidance can unlock RWE’s full potential in supporting EU JCA submissions.
- 8 April 2026
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 14 (2) , 20
Open AccessMapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization
Methodological guidelines for real-world evidence (RWE) in European Union (EU) joint clinical assessments (JCA) are lacking. This manuscript explores RWE potential in EU health technology assessment (HTA) and offers recommendations for generating high-quality RWE. An environmental scan of peer-reviewed and gray literature was conducted to review RWE frameworks and documents in EU regulatory and HTA decision-making. Extraction elements were standardized across key RWE themes: data quality, methodological rigor, stakeholder engagement, and applications. In JCA, RWE has multiple uses, including informing PICO simulation exercises, understanding disease landscape, identifying prognostic factors and effect modifiers, and directly or indirectly informing comparative clinical assessments. Methodological guidance from the HTA Coordination Group is limited to cases in which evidence from non-randomized studies is used as direct inputs in comparative assessments. Individual HTA bodies provide more detailed guidance, missing an opportunity to leverage RWE within JCAs that can offer insight for local Member State submissions. Generating high-quality RWE that is credible, actionable, and acceptable for JCA submissions and local HTA bodies requires careful attention to methodological considerations and early planning. Broader RWE integration that reflects patient journeys is needed. Expanding the HTA Coordination Group guidance can unlock RWE’s full potential in supporting EU JCA submissions.
- Open Access
- 10 April 2023
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 23 (5) , 579-589
Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States
Clinical outcomes in chronic lymphocytic leukemia (CLL) have improved with targeted therapy, including Bruton tyrosine kinase inhibitors such as acalabrutinib.A semi-Markov model with 3 health stat...
- 10 April 2023
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 23 (5) , 579-589
Open AccessCost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States
Clinical outcomes in chronic lymphocytic leukemia (CLL) have improved with targeted therapy, including Bruton tyrosine kinase inhibitors such as acalabrutinib.A semi-Markov model with 3 health stat...
- Open Access
- 7 December 2022
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 14, 3421-3435
Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors
Background: To extend the discussion on the use of real-world evidence (RWE) in conveying the clinical value of treatment beyond trial data, the primary objective of this study was to assess if efficacy gains in progression-free survival (PFS) observed in randomized controlled trials (RCT) correlate with efficacy gains in the real-world setting. For this, we assessed the treatment benefit of three tyrosine kinase inhibitors (TKIs) in aNSCLC. Methods: Using matched cohorts identified in the Flatiron Health database (2011– 2020), we mimicked the following cohorts of TKI versus platinum-based chemotherapy (PBC) from the following trials: (1) erlotinib, EURTAC; (2) afatinib, LUX-Lung 3; and (3) crizotinib, PROFILE 1014. Time to treatment discontinuation (TTD) hazard ratio (HR) was used as a proxy for PFS HR, the primary endpoint in the selected RCTs. HRs were calculated via Cox proportional hazard models. Results: Overall, 1,118 patients were included across the three RWE cohorts. Frontline TKI regimens had statistically significantly better real-world TTD than their matched PBC comparator group (HR 0.37, 95% confidence interval [CI] 0.30– 0.44 for erlotinib; HR 0.42, 95% CI 0.32– 0.55 for afatinib; HR 0.37, 95% CI 0.26– 0.53 for crizotinib). The benefit in real-world OS was not different between TKIs and PBC patients, attributed to a high proportion of switching to subsequent therapy. Study findings of relative treatment benefit (HR) for real-world TTD and OS were deemed similar to those for PFS and OS from the pivotal RCTs. Conclusion: The relative treatment effect, measured as real-world TTD HR over the long term, was similar to trial-based PFS HR, implying that the clinical benefit of aNSCLC treatments conveyed in trials translated into the clinical setting. This is important, given that OS data interpretation is limited, even with longer follow-up. Additionally, our RWE analysis endorses TTD as a relevant endpoint to measure clinical benefit.
- 7 December 2022
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 14, 3421-3435
Open AccessConsiderations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors
Background: To extend the discussion on the use of real-world evidence (RWE) in conveying the clinical value of treatment beyond trial data, the primary objective of this study was to assess if efficacy gains in progression-free survival (PFS) observed in randomized controlled trials (RCT) correlate with efficacy gains in the real-world setting. For this, we assessed the treatment benefit of three tyrosine kinase inhibitors (TKIs) in aNSCLC. Methods: Using matched cohorts identified in the Flatiron Health database (2011– 2020), we mimicked the following cohorts of TKI versus platinum-based chemotherapy (PBC) from the following trials: (1) erlotinib, EURTAC; (2) afatinib, LUX-Lung 3; and (3) crizotinib, PROFILE 1014. Time to treatment discontinuation (TTD) hazard ratio (HR) was used as a proxy for PFS HR, the primary endpoint in the selected RCTs. HRs were calculated via Cox proportional hazard models. Results: Overall, 1,118 patients were included across the three RWE cohorts. Frontline TKI regimens had statistically significantly better real-world TTD than their matched PBC comparator group (HR 0.37, 95% confidence interval [CI] 0.30– 0.44 for erlotinib; HR 0.42, 95% CI 0.32– 0.55 for afatinib; HR 0.37, 95% CI 0.26– 0.53 for crizotinib). The benefit in real-world OS was not different between TKIs and PBC patients, attributed to a high proportion of switching to subsequent therapy. Study findings of relative treatment benefit (HR) for real-world TTD and OS were deemed similar to those for PFS and OS from the pivotal RCTs. Conclusion: The relative treatment effect, measured as real-world TTD HR over the long term, was similar to trial-based PFS HR, implying that the clinical benefit of aNSCLC treatments conveyed in trials translated into the clinical setting. This is important, given that OS data interpretation is limited, even with longer follow-up. Additionally, our RWE analysis endorses TTD as a relevant endpoint to measure clinical benefit.
- 19 October 2010
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 11 (6) , 597-598
Cost-effectiveness analysis, welfare economics, and the societal perspective: a reply
- 19 October 2010
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 11 (6) , 597-598
Cost-effectiveness analysis, welfare economics, and the societal perspective: a reply
- 5 April 2010
- Published by Wiley in Health Economics
- Vol. 20 (1) , 68-72
Welfare, QALYs, and costs - a comment
- 5 April 2010
- Published by Wiley in Health Economics
- Vol. 20 (1) , 68-72
Welfare, QALYs, and costs - a comment
- 3 March 2009
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 11 (1) , 5-13
On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected
Cost-effectiveness analysis, Non-medical costs, QALYs, Welfare economics, D61, D81, I10,
- 3 March 2009
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 11 (1) , 5-13
On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected
Cost-effectiveness analysis, Non-medical costs, QALYs, Welfare economics, D61, D81, I10,
- 5 September 2007
- Published by Wiley in Health Economics
- Vol. 17 (5) , 579-591
On future non‐medical costs in economic evaluations
Economic evaluation in health care is still an evolving discipline. One of the current controversies in cost‐effectiveness analysis regards the inclusion or exclusion of future non‐medical costs (i.e. consumption net of production) due to increased survival. This paper examines the implications of a symmetry rule stating that there should be consistency between costs included in the numerator and utility aspects included in the denominator. While the observation that no quality‐adjusted life year (QALY) instruments explicitly include consumption and leisure seems to give support to the notion that future non‐medical costs should be excluded when QALYs are used as the outcome measure, a better understanding of what respondents actually consider when reporting QALY weights is required. However, the more fundamental question is whether QALYs can be interpreted as utilities. Or more precisely, what are the assumptions needed for a general utility model also including consumption and leisure to be consistent with QALYs? Once those assumptions are identified, they need to be experimentally tested to see whether they are at least approximately valid. Until we have answers to these areas for future research, it seems premature to include future non‐medical costs. Copyright © 2007 John Wiley & Sons, Ltd.
- 5 September 2007
- Published by Wiley in Health Economics
- Vol. 17 (5) , 579-591
On future non‐medical costs in economic evaluations
Economic evaluation in health care is still an evolving discipline. One of the current controversies in cost‐effectiveness analysis regards the inclusion or exclusion of future non‐medical costs (i.e. consumption net of production) due to increased survival. This paper examines the implications of a symmetry rule stating that there should be consistency between costs included in the numerator and utility aspects included in the denominator. While the observation that no quality‐adjusted life year (QALY) instruments explicitly include consumption and leisure seems to give support to the notion that future non‐medical costs should be excluded when QALYs are used as the outcome measure, a better understanding of what respondents actually consider when reporting QALY weights is required. However, the more fundamental question is whether QALYs can be interpreted as utilities. Or more precisely, what are the assumptions needed for a general utility model also including consumption and leisure to be consistent with QALYs? Once those assumptions are identified, they need to be experimentally tested to see whether they are at least approximately valid. Until we have answers to these areas for future research, it seems premature to include future non‐medical costs. Copyright © 2007 John Wiley & Sons, Ltd.
- 1 January 2001
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (4) , 323-335
On Individual Preferences and Aggregation in Economic Evaluation in Healthcare
For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals’ willingness to pay (WTP) or...
- 1 January 2001
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (4) , 323-335
On Individual Preferences and Aggregation in Economic Evaluation in Healthcare
For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals’ willingness to pay (WTP) or...
- 28 August 2000
- Published by Elsevier in Journal of Health Economics
- Vol. 19 (5) , 821-827
Insurance and imperfect financial markets in Grossman's demand for health model — a reply to Tabata and Ohkusa
- 28 August 2000
- Published by Elsevier in Journal of Health Economics
- Vol. 19 (5) , 821-827
Insurance and imperfect financial markets in Grossman's demand for health model — a reply to Tabata and Ohkusa
- 1 May 2000
- Published by Elsevier in Health Policy
- Vol. 52 (1) , 53-70
On hypothetical bias and calibration in cost–benefit studies
- 1 May 2000
- Published by Elsevier in Health Policy
- Vol. 52 (1) , 53-70
On hypothetical bias and calibration in cost–benefit studies